Latest Pathkey.AI (ASX:PKY) News

Big moves came from small and mid-cap names tied to drilling, project studies and fresh funding. Healthcare, mining and takeover stocks all had a busy week, but not every strong announcement held its gains.

Small-cap tech trading was split between one huge contract-driven winner and a long list of capital raisings, AI launches and legal worries. Orcoda surged, ClearVue slumped, and Credit Clear fell hard as investors picked between real revenue, fresh funding and rising uncertainty.

Pathkey.AI has finalised its takeover of Chipforge, an AI-driven semiconductor design company, issuing shares and performance rights as consideration. The move broadens Pathkey's AI platform capabilities from clinical trials into semiconductor engineering, aiming to shorten chip development cycles significantly.

Space batteries, telecom AI and a healthcare software leadership change drove the week’s biggest moves in small-cap tech. Capital raisings and debt deals also shaped trading, with several early jumps fading as investors weighed dilution and execution risk.

PathKey.AI (ASX:PKY) confirmed no undisclosed price-sensitive information amid a recent jump in its share price and trading volume, attributing the move to prior announcements and investor interest in AI opportunities.

Big contract wins and fresh capital drove the strongest gains in local tech, led by FirstWave, Megaport and Aristocrat Leisure. Smaller speculative names were less stable, with several gap re-openings losing steam as investors sold into early excitement.

Pathkey.AI appoints Andrew Farnsworth as CEO, leveraging his defence and AI expertise to drive commercialisation of TrialKey and Chipforge platforms.

A brutal sell-off in PEXA swamped an otherwise upbeat week for small-cap tech, where contract wins and product launches did the heavy lifting. RocketBoots led the gainers as investors paid up for near-term rollout revenue, while Adveritas rallied on a big push into self-serve SME sales.

Pathkey.AI has secured a significant commercial contract with Imunexus Therapeutics, deploying its AI-driven TrialKey platform to enhance early-phase clinical trial design and capital raising efforts.

FortifAI’s funding and big claims around faster AI data processing drove the week’s loudest move, while two small caps jumped on price queries. Elsewhere, results season rewarded clear recurring revenue growth, but punished gaps where early buying didn’t stick.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.